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Implantable cardioverter defibrillators (ICDs) are an
established therapy for the prevention of sudden cardiac death.
Since the 1990s multiple primary and secondary prevention
trials, such as AVID, MADIT-I and II and SCD-HeFT, have
demonstrated a significant reduction in mortality in patients
with ischaemic and non-ischaemic cardiomyopathy, especial-
ly in survivors of ventricular arrhythmias causing
haemodynamic compromise. Today, expanding indications,
mainly for prophylactic device implantation, cause a steep
growth of ICD implantations worldwide [1]. However, not
all patients eligible for prophylactic ICD therapy are likely to
experience ICD therapy, and therefore benefit, within a rea-
sonable time horizon. Assessment of multiple risk factors can
more clearly identify patients at risk in whom ICD efficacy
may be different from what was demonstrated in the large
randomised ICD trials.
In this issue of the Netherlands Heart Journal Wijers et
al. [1] present an extensive real-world clinical study in
which they sought to determine in which patients sudden
cardiac death was actually prevented with ICD implantation.
They demonstrate that 21 % of the 1075 patients receiving an
ICD between 2006 and 2011 (61 % primary prevention)
received appropriate shocks during a median follow-up of
31 months. They report that ischaemic cardiomyopathy, an
LVEF ≤25 % and male gender were independently associated
with appropriate shock therapy. Also, they find that 14 % of
the patients implanted with an ICD died during a 31-month
follow-up, of whom 9.7 % did not receive prior appropriate
therapy and 4.7 % died within the first year after ICD implan-
tation. Predictors for mortality are, however, quite similar to
the predictors for appropriate shocks [1]. ICD efficacy in
terms of survival rather than in terms of appropriate therapy
may therefore be questioned in high-risk subgroups of patients
with multiple risk factors in whom the short-term risk of
nonarrhythmic death may predominate despite ICD therapy.
These risk factors are defined by Goldenberg et al. [2] as >3 of
the following: NYHA class >II, age >70 years, impaired renal
function, QRS duration >120 ms or atrial fibrillation. Con-
versely, there are also low-risk subgroups consisting of pa-
tients without any risk factors who actually have a very low
annualised need for truly lifesaving therapy [2].
While the presumed benefit of ICDs is reflected in the
indications for ICD implantation in the guidelines, which
are predominantly based on the ICD efficacy, the associated
harm (such as inappropriate shocks and implant and long-
term complications) receives less attention. Multiple studies
demonstrate that the inappropriate shock rate in the general
ICD population is approximately 3 % per year, and higher
numbers are reported in patients with a history of atrial
fibrillation and, generally younger, patients with inherited
or congenital heart diseases [3, 4]. This number of inappro-
priate shocks can safely and substantially be reduced by
contemporary ICD programming, whichWijers et al. likewise
suggest as an explanation for the low inappropriate shock rate
in their study. ICD-related complications are reported in 5 %
of the ICD patients per year and complication rates may
increase with multiple lead and device replacements [3].
ICD patients are exposed to both implantation-related compli-
cations such as pneumothorax and heart perforation and long-
term complications such as vein occlusions and consequences
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of lead fractures [3, 4]. Despite advances in ICD system design
and manufacturing, devices remain imperfect. Failures of lead
design, such as with the Sprint Fidelis and Riata lead, can lead
to inappropriate sensing due to electrical noise with resultant
inappropriate shocks. Complication rates are, however, not
consequently reported in the large randomised ICD trials and
appear to be a suppositious child, while substantially contrib-
uting to the morbidity and even mortality of ICD patients.
Moreover, ICD therapy may lead to a psychological
burden. Studies consistently show impairments in health
status and quality of life in ICD patients, with an elevated
risk for anxiety and depression in up to 30 % of the patients.
ICDs exacerbate psychological distress and the experience
of one or more ICD shocks further negatively affects quality
of life [5].
Finally, ICD therapy is expensive to society, with high
costs at implantation. Earlier studies demonstrate a reason-
able cost-effectiveness for prophylactic ICD therapy [6].
However, patient comorbidities affect long-term prognosis
which might limit the cost-effectiveness whereas more ex-
tensive risk stratification could increase the effectiveness
further. With increasing burden on health care budgets it
should be questioned from a society perspective whether
ICD therapy in patients who are less likely to benefit from
ICD therapy is preferable.
Hence, when judging the price of ICD therapy, ICD-
related adverse events, ICD-related psychological dis-
tress and cost-effectiveness need to be taken into ac-
count. This however, does not imply that prophylactic
ICDs should not be implanted in patients in whom the
indication can be debated, because the severity of the
chance of sudden cardiac death may outweigh the
chance of harm. An inappropriate shock or ICD-related
complication may then be considered an acceptable,
minor complication of ICD therapy in the context of
prevention of sudden cardiac death, particularly in pa-
tients with concurrent appropriate shock therapy. How-
ever, patients with ICD harm but without appropriate shocks
obviously pay the price for ICD therapy. Evolving technology
may continuously change the balance between benefit and
harm. This notwithstanding, risk taking is essential to success
in any goal where the stakes are high. A patient-tailored risk
stratification for a better benefit-harm equilibrium seems cur-
rently underdeveloped but certainly needed; and Wijers et al.
should therefore be commended on clarifying which patients
have the most benefit of their ICD [1].
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